AU6323686A – Monoclonal antibodies binding determinants of gram negative bacteria
– Google Patents
AU6323686A – Monoclonal antibodies binding determinants of gram negative bacteria
– Google Patents
Monoclonal antibodies binding determinants of gram negative bacteria
Info
Publication number
AU6323686A
AU6323686A
AU63236/86A
AU6323686A
AU6323686A
AU 6323686 A
AU6323686 A
AU 6323686A
AU 63236/86 A
AU63236/86 A
AU 63236/86A
AU 6323686 A
AU6323686 A
AU 6323686A
AU 6323686 A
AU6323686 A
AU 6323686A
Authority
AU
Australia
Prior art keywords
monoclonal antibodies
negative bacteria
gram negative
antibodies binding
binding determinants
Prior art date
1985-09-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU63236/86A
Other versions
AU606581B2
(en
Inventor
Susan Alam
Lowell S. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1985-09-27
Filing date
1986-09-29
Publication date
1987-04-02
1985-09-27
Priority claimed from US06/781,242
external-priority
patent/US4777136A/en
1986-09-29
Application filed by University of California
filed
Critical
University of California
1987-04-02
Publication of AU6323686A
publication
Critical
patent/AU6323686A/en
1991-02-14
Application granted
granted
Critical
1991-02-14
Publication of AU606581B2
publication
Critical
patent/AU606581B2/en
2006-09-29
Anticipated expiration
legal-status
Critical
Status
Ceased
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
C12N5/10—Cells modified by introduction of foreign genetic material
C12N5/12—Fused cells, e.g. hybridomas
G—PHYSICS
G01—MEASURING; TESTING
G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 – G01N31/00
G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
G01N33/56911—Bacteria
G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K38/00—Medicinal preparations containing peptides
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K2317/00—Immunoglobulins specific features
C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
C07K2317/77—Internalization into the cell
G—PHYSICS
G01—MEASURING; TESTING
G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
G01N2333/21—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Pseudomonadaceae (F)
G—PHYSICS
G01—MEASURING; TESTING
G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
G01N2400/50—Lipopolysaccharides; LPS
Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
Y10S530/809—Fused cells, e.g. hybridoma
Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
Y10S530/82—Proteins from microorganisms
Y10S530/825—Bacteria
Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
Y10S530/864—Monoclonal
AU63236/86A
1985-09-27
1986-09-29
Monoclonal antibodies binding determinants of gram negative bacteria
Ceased
AU606581B2
(en)
Applications Claiming Priority (4)
Application Number
Priority Date
Filing Date
Title
US781242
1985-09-27
US06/781,242
US4777136A
(en)
1985-09-27
1985-09-27
Monoclonal antibody reactive with Pseudomonas Aeruginosa
US06/855,878
US4918163A
(en)
1985-09-27
1986-04-24
Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US855878
1986-04-24
Publications (2)
Publication Number
Publication Date
AU6323686A
true
AU6323686A
(en)
1987-04-02
AU606581B2
AU606581B2
(en)
1991-02-14
Family
ID=27119830
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
AU63236/86A
Ceased
AU606581B2
(en)
1985-09-27
1986-09-29
Monoclonal antibodies binding determinants of gram negative bacteria
Country Status (11)
Country
Link
US
(2)
US4918163A
(en)
EP
(1)
EP0217527B1
(en)
JP
(1)
JP2539797B2
(en)
KR
(1)
KR910002427B1
(en)
AU
(1)
AU606581B2
(en)
DE
(1)
DE3686931T2
(en)
ES
(1)
ES2004340A6
(en)
IE
(1)
IE59685B1
(en)
IL
(1)
IL79719A
(en)
NZ
(1)
NZ217283A
(en)
PH
(1)
PH26525A
(en)
Families Citing this family (72)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US5179018A
(en)
*
1983-10-14
1993-01-12
Centocor, Inc.
Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
IL81370A
(en)
*
1986-02-07
1991-06-30
Genetic Systems Corp
Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
DK172840B1
(en)
*
1986-07-03
1999-08-09
Genetic Systems Corp
Monoclonal antibodies to Pseudomonas aeruginosa flagella, pharmaceutical preparations containing such antibodies, and c.
US5521085A
(en)
*
1986-12-15
1996-05-28
Mitsui Toatsu Chemicals, Inc.
Transformed cell lines producing human monoclonal antibodies specific for Pseudomonas aeruginosa serotypes
JP2725041B2
(en)
*
1986-12-15
1998-03-09
三井東圧化学株式会社
Human monoclonal antibody and its preventive and therapeutic agent for infectious diseases
AU1807188A
(en)
*
1987-04-10
1988-11-04
Xoma Corporation
Human monoclonal antibodies binding determinants of gram negative bacteria
GB2218703B
(en)
*
1988-05-10
1992-10-28
Sumitomo Chemical Co
Human monoclonal antibody to p.aeruginosa: its production and use
US5888519A
(en)
*
1988-06-02
1999-03-30
The United States Of America As Represented By The Secretary Of The Army
Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
US5594113A
(en)
*
1988-06-23
1997-01-14
Associates Of Cape Cod, Inc.
Endotoxin binding and neutralizing protein and uses thereof
EP0374296B1
(en)
*
1988-12-22
1995-02-01
Dade International Inc.
Lipohaptens and use of carrier-bound lipohaptens in immunoassays
DE3843784A1
(en)
*
1988-12-24
1990-06-28
Battelle Institut E V
Method for the detection of Gram-negative microorganisms, and DNA probes and antibodies suitable for this purpose
JPH02283294A
(en)
*
1989-04-24
1990-11-20
Sumitomo Chem Co Ltd
Human monoclonal antibody
DE69032662T2
(en)
*
1989-08-01
1999-03-11
Scripps Research Inst
METHOD AND COMPOSITIONS FOR IMPROVING THE SYMPTOMS OF SEPSIS
US6075121A
(en)
*
1990-05-15
2000-06-13
Chiron Corporation
Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
US5198339A
(en)
*
1990-07-13
1993-03-30
Board Of Regents, The University Of Texas System
Method for detection of gram-negative bacterial lipopolysaccharides in biological fluids
CA2094588A1
(en)
*
1990-10-22
1992-04-23
Carl R. Alving
Lipid a composition as immunogenic agents to prevent or treat gram-negative bacterial infections
US5773280A
(en)
*
1992-03-20
1998-06-30
The Board Of Trustees Of The University Of Illinois
Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
US5434075A
(en)
*
1992-03-20
1995-07-18
Board Of Trustees Of The University Of Illinois
Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
US5994088A
(en)
*
1991-03-08
1999-11-30
Board Of Trustees Of The University Of Illinois
Methods and reagents for preparing and using immunological agents specific for P-glycoprotein
US5233024A
(en)
*
1991-04-09
1993-08-03
The Brigham & Women’s Hospital
Anti-idiotypic monoclonal antibodies for mucoid pseudomonas aeruginosa, their preparation and use
AU2006892A
(en)
*
1991-05-16
1992-12-30
Associates Of Cape Cod, Inc.
Endotoxin binding and neutralizing protein and uses thereof
US5279956A
(en)
*
1991-06-24
1994-01-18
The Scripps Research Institute
Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5370872A
(en)
*
1991-08-12
1994-12-06
Swiss Serum And Vaccine Institute Berne
Escherichia coliO-polysaccharide-protein conjugate vaccine
AU660325B2
(en)
*
1991-10-11
1995-06-22
Eisai Co. Ltd.
Anti-endotoxin compounds and related molecules and methods
US5530113A
(en)
*
1991-10-11
1996-06-25
Eisai Co., Ltd.
Anti-endotoxin compounds
PL177771B1
(en)
*
1992-12-18
2000-01-31
Cell Med Inc
Diagnostic test and therapy for demyelination diseases such as multiple sclerosis
US6660267B1
(en)
1992-12-21
2003-12-09
Promega Corporation
Prevention and treatment of sepsis
AU693433B2
(en)
*
1992-12-21
1998-07-02
Promega Corporation
Prevention and treatment of sepsis
US5545721A
(en)
*
1992-12-21
1996-08-13
Ophidian Pharmaceuticals, Inc.
Conjugates for the prevention and treatment of sepsis
ES2138662T3
(en)
1993-06-03
2000-01-16
Therapeutic Antibodies Inc
PRODUCTION OF ANTIBODY FRAGMENTS.
US5648343A
(en)
*
1994-02-28
1997-07-15
The University Of Georgia Research Foundation
Method for treating LPS-mediated disorders
WO1995029662A2
(en)
*
1994-04-20
1995-11-09
U.S. Department Of The Army
Vaccine against gram-negative bacterial infections
US5807694A
(en)
*
1995-09-07
1998-09-15
Economic Innovation And Technology Council, University Of Manitoba
Detection of salmonella enteritidis and other pathogenic microorganisms and monoclonal antibody useful therefor
US6962702B2
(en)
1998-06-22
2005-11-08
Immunomedics Inc.
Production and use of novel peptide-based agents for use with bi-specific antibodies
US8383081B2
(en)
*
1999-05-10
2013-02-26
Immunomedics, Inc.
Anti-CD74 immunoconjugates and methods of use
US7829064B2
(en)
*
1999-05-10
2010-11-09
Immunomedics, Inc.
Anti-CD74 immunoconjugates and methods
US8119101B2
(en)
*
1999-05-10
2012-02-21
The Ohio State University
Anti-CD74 immunoconjugates and methods of use
AU2008202582C1
(en)
*
1999-07-16
2012-04-05
Verax Biomedical, Inc.
Method and kit immuno-detecting bacteria in blood and tissues
CZ300108B6
(en)
*
1999-07-16
2009-02-11
Verax Biomedical, Inc.
Method for screening for the presence of a clinically relevant amount of Gram-positive and/or Gram-negative bacteria in donor blood or blood product or donor tissue and kit for making the method
US6790661B1
(en)
1999-07-16
2004-09-14
Verax Biomedical, Inc.
System for detecting bacteria in blood, blood products, and fluids of tissues
US9770517B2
(en)
2002-03-01
2017-09-26
Immunomedics, Inc.
Anti-Trop-2 antibody-drug conjugates and uses thereof
DK1483294T3
(en)
2002-03-01
2010-11-08
Immunomedics Inc
Internalizing anti-CD74 antibodies and methods for their use
DE10247430A1
(en)
*
2002-10-11
2004-04-29
Fresenius Hemocare Gmbh
Method for determining the level of endotoxins in liquids
US8420086B2
(en)
2002-12-13
2013-04-16
Immunomedics, Inc.
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US8883160B2
(en)
*
2004-02-13
2014-11-11
Ibc Pharmaceuticals, Inc.
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2
(en)
2004-02-13
2017-01-24
Ibc Pharmaceuticals, Inc.
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9707302B2
(en)
2013-07-23
2017-07-18
Immunomedics, Inc.
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10058621B2
(en)
2015-06-25
2018-08-28
Immunomedics, Inc.
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US8349332B2
(en)
2005-04-06
2013-01-08
Ibc Pharmaceuticals, Inc.
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2
(en)
2005-04-06
2013-07-02
Ibc Pharmaceuticals, Inc.
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US20070254322A1
(en)
*
2006-05-01
2007-11-01
Romaschin Alexander D
Complement-based analyte assay
US8715949B2
(en)
*
2006-09-07
2014-05-06
The United States Of America, As Represented By The Secretary Of The Navy
Applications of the binding interaction of proanthocyanidins with bacteria and bacterial components
EP2523680A4
(en)
*
2010-01-11
2013-06-19
Ct Molecular Med & Immunology
Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
US9757458B2
(en)
2011-12-05
2017-09-12
Immunomedics, Inc.
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
EP2788020A4
(en)
2011-12-05
2015-04-29
Immunomedics Inc
Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US9931417B2
(en)
2012-12-13
2018-04-03
Immunomedics, Inc.
Antibody-SN-38 immunoconjugates with a CL2A linker
US10206918B2
(en)
2012-12-13
2019-02-19
Immunomedics, Inc.
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9492566B2
(en)
2012-12-13
2016-11-15
Immunomedics, Inc.
Antibody-drug conjugates and uses thereof
US10137196B2
(en)
2012-12-13
2018-11-27
Immunomedics, Inc.
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
KR20230078823A
(en)
2012-12-13
2023-06-02
이뮤노메딕스, 인코오포레이티드
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10413539B2
(en)
2012-12-13
2019-09-17
Immunomedics, Inc.
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10744129B2
(en)
2012-12-13
2020-08-18
Immunomedics, Inc.
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
ES2819573T3
(en)
2012-12-13
2021-04-16
Immunomedics Inc
Method for Producing Antibody-SN-38 Immunoconjugates with a CL2A Linker
US11253606B2
(en)
2013-07-23
2022-02-22
Immunomedics, Inc.
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
JP6746845B2
(en)
2015-04-22
2020-08-26
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ．
Isolation, detection, diagnosis and/or characterization of circulating TROP-2 positive cancer cells
US10195175B2
(en)
2015-06-25
2019-02-05
Immunomedics, Inc.
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US9913903B2
(en)
2015-08-06
2018-03-13
Grifols Worldwide Operations Limited
Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM
US10570194B2
(en)
2015-08-06
2020-02-25
Grifols Worldwide Operations Limited
Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)
US20170224837A1
(en)
2016-02-10
2017-08-10
Immunomedics, Inc.
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
RU2725292C2
(en)
2016-04-27
2020-06-30
Иммьюномедикс, Инк.
Efficacy of conjugates of anti-trop-2 antibody with drug sn-38 for therapy of recurrent/refractory to inhibitors of tumor control point
EP3600283A4
(en)
2017-03-27
2020-12-16
Immunomedics, Inc.
Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
WO2018187074A1
(en)
2017-04-03
2018-10-11
Immunomedics, Inc.
Subcutaneous administration of antibody-drug conjugates for cancer therapy
Family Cites Families (26)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US4647447A
(en)
*
1981-07-24
1987-03-03
Schering Aktiengesellschaft
Diagnostic media
US4443549A
(en)
*
1981-10-19
1984-04-17
Molecular Genetics, Inc.
Production of monoclonal antibodies against bacterial adhesins
US4428931A
(en)
*
1982-03-15
1984-01-31
Merck & Co., Inc.
Bacterial toxoids and gram-negative immune globulin therefrom
US4464465A
(en)
*
1982-04-05
1984-08-07
Genetic Systems Corporation
Cell-driven viral transfer in eukaryotes
FI69639C
(en)
*
1982-07-02
1986-03-10
Orion Yhtymae Oy
PREPARAT FOER ANVAENDNING VID KLAMYDIA-DIAGNOSTIK
JPS5929622A
(en)
*
1982-08-10
1984-02-16
Meiji Seika Kaisha Ltd
Monoclonal antibody, preparation and use thereof
US4689299A
(en)
*
1982-09-30
1987-08-25
University Of Rochester
Human monoclonal antibodies against bacterial toxins
US4525453A
(en)
*
1982-10-26
1985-06-25
Eastman Kodak Company
Process for rapidly differentiating between gram-negative and gram-positive microorganisms
US4574116A
(en)
*
1983-01-13
1986-03-04
The Board Of Trustees Of The Leland Stanford Jr. University
Methods and cell lines for immortalization and monoclonal antibody production by antigen-stimulated B-lymphocytes
DE3303649A1
(en)
*
1983-02-03
1984-08-09
Wacker-Chemie GmbH, 8000 München
EXCLUDING WATER STORAGE CROSS-LINKABLE DIMENSIONS WHEN THE WATER ACCESSES AT ROOM TEMPERATURE
US5057598A
(en)
*
1983-05-06
1991-10-15
Centocor, Inc.
Monoclonal antibodies reactive with endotoxin core
EP0286099A3
(en)
*
1983-05-06
1988-12-21
Velos Group
Monoclonal antibodies reactive with endotoxin core
US4587121A
(en)
*
1983-06-14
1986-05-06
Miles Laboratories, Inc.
High titer Pseudomonas immune serum globulin
US4525465A
(en)
*
1983-10-07
1985-06-25
Nippon Kayaku Kabushiki Kaisha
Water-insoluble biospecific absorbent containing argininal derivative
US5179018A
(en)
*
1983-10-14
1993-01-12
Centocor, Inc.
Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US4617264A
(en)
*
1983-11-04
1986-10-14
Syntex (U.S.A.) Inc.
Pretreatment method and composition
EP0168422A1
(en)
*
1983-12-12
1986-01-22
Meru, Inc.
Method and materials for the identification of lipopolysaccharide producing microorganisms
US4683196A
(en)
*
1983-12-12
1987-07-28
Meru, Inc.
Method and materials for the identification of lipopolysaccharide producing microorganisms
US4596769A
(en)
*
1984-03-05
1986-06-24
Temple University
Monoclonal antibodies to peptidoglycan and methods of preparing same
US4834975A
(en)
*
1984-05-25
1989-05-30
Genetics Corporation
Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
US4646465A
(en)
*
1984-06-22
1987-03-03
Suiseki Fujimoto
Method of inoculating mushroom basidiospores seed basidiospore bed for inoculation, culture container for seed basidiospore bed, and boring apparatus for host wood for inoculation
FI853395L
(en)
*
1984-09-05
1986-03-06
Cetus Corp
MONOCLONAL ANTICROPPAR SOM BLOCKERAR GRAM-NEGATIVE BACTERIEENDOTOXIN.
JP2691708B2
(en)
*
1984-09-26
1997-12-17
住友製薬株式会社
Human monoclonal antibody and method for producing the same
EP0183876A1
(en)
*
1984-11-27
1986-06-11
The Board Of Trustees Of The Leland Stanford Junior University
Monoclonal antibodies for endotoxin core and their use
EP0233289B1
(en)
*
1984-12-26
1993-03-10
Teijin Limited
Hybridomas producing anti-pseudomonas aeruginosa human monoclonal antibody
CA2300446C
(en)
*
2000-03-10
2009-05-19
Stan Mcclean
Beverage brewing apparatus having automatic and semi-automatic brewing modes
1986
1986-04-24
US
US06/855,878
patent/US4918163A/en
not_active
Expired – Fee Related
1986-08-14
IL
IL79719A
patent/IL79719A/en
not_active
IP Right Cessation
1986-08-19
DE
DE8686306420T
patent/DE3686931T2/en
not_active
Expired – Fee Related
1986-08-19
EP
EP86306420A
patent/EP0217527B1/en
not_active
Expired – Lifetime
1986-08-20
NZ
NZ217283A
patent/NZ217283A/en
unknown
1986-09-25
PH
PH34297A
patent/PH26525A/en
unknown
1986-09-26
ES
ES8602198A
patent/ES2004340A6/en
not_active
Expired
1986-09-26
IE
IE254686A
patent/IE59685B1/en
not_active
IP Right Cessation
1986-09-27
KR
KR1019860008128A
patent/KR910002427B1/en
not_active
IP Right Cessation
1986-09-27
JP
JP61229481A
patent/JP2539797B2/en
not_active
Expired – Lifetime
1986-09-29
AU
AU63236/86A
patent/AU606581B2/en
not_active
Ceased
1994
1994-07-01
US
US08/277,934
patent/US5484591A/en
not_active
Expired – Fee Related
Also Published As
Publication number
Publication date
US5484591A
(en)
1996-01-16
EP0217527B1
(en)
1992-10-07
DE3686931D1
(en)
1992-11-12
IE862546L
(en)
1987-03-27
NZ217283A
(en)
1991-07-26
JPS62228295A
(en)
1987-10-07
KR910002427B1
(en)
1991-04-22
JP2539797B2
(en)
1996-10-02
EP0217527A2
(en)
1987-04-08
PH26525A
(en)
1992-08-07
IE59685B1
(en)
1994-03-23
DE3686931T2
(en)
1993-04-29
IL79719A
(en)
1991-06-10
US4918163A
(en)
1990-04-17
ES2004340A6
(en)
1989-01-01
AU606581B2
(en)
1991-02-14
KR870003195A
(en)
1987-04-15
IL79719A0
(en)
1986-11-30
EP0217527A3
(en)
1989-02-08
US4918163B1
(en)
1993-08-17
Similar Documents
Publication
Publication Date
Title
AU6323686A
(en)
1987-04-02
Monoclonal antibodies binding determinants of gram negative bacteria
AU1480388A
(en)
1988-10-10
Altered antibodies
GB8629540D0
(en)
1987-01-21
Monoclonal antibodies
AU6373286A
(en)
1987-03-24
Auto-anti-idiotypic monoclonal antibodies to steroid receptals and uses thereof
AU550364B2
(en)
1986-03-20
Immunogen of lidocaine-protein conjugate and antibodies derived therefrom
AU3529889A
(en)
1989-10-12
Specific cea-family antigens, antibodies specific and their methods of use
ZA867342B
(en)
1987-06-24
Monoclonal antibodies binding determinants of grams negative bacteria
AU5444386A
(en)
1986-09-11
Anti-nicotine and anti-cotinine antibodies (monoclonal and polyclonal)
AU549614B2
(en)
1986-02-06
Fermented vegetable – hydrolysed protein flavourant
AU543744B2
(en)
1985-05-02
Modification of micro-organisms
EP0310413A3
(en)
1989-12-13
Immobilized antibodies
ZA869171B
(en)
1987-08-26
Monoclonal antibodies
AU1807188A
(en)
1988-11-04
Human monoclonal antibodies binding determinants of gram negative bacteria
GB8826392D0
(en)
1988-12-14
Immobilized antibodies
AU2383288A
(en)
1989-04-17
Human anti-rh(d) monoclonal antibodies
GB8517895D0
(en)
1985-08-21
Monoclonal antibodies
AU7649187A
(en)
1988-01-29
Preparation of monoclonal antibodies
AU2111088A
(en)
1989-03-02
Carrier of antigen or antibody
GB8506373D0
(en)
1985-04-11
Antigens antibodies
AU5736286A
(en)
1986-11-20
Rotavirus antigens
AU618720B2
(en)
1992-01-09
Monoclonal antibodies
AU5675790A
(en)
1990-11-29
Human monoclonal antibodies to sero-specific determinants of gram-negative bacteria
AU2521288A
(en)
1989-04-17
Human anti-rh(d) monoclonal antibodies
GB2175918B
(en)
1989-06-28
Monoclonal antibodies
GB8517896D0
(en)
1985-08-21
Monoclonal antibodies
None